These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy. Fernandez-Rivas M; Vereda A; Vickery BP; Sharma V; Nilsson C; Muraro A; Hourihane JO; DunnGalvin A; du Toit G; Blumchen K; Beyer K; Smith A; Ryan R; Adelman DC; Jones SM Allergy; 2022 Mar; 77(3):991-1003. PubMed ID: 34320250 [TBL] [Abstract][Full Text] [Related]
8. Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts. Berin MC; Agashe C; Burks AW; Chiang D; Davidson WF; Dawson P; Grishin A; Henning AK; Jones SM; Kim EH; Leung DYM; Masilamani M; Scurlock AM; Sicherer SH; Wood RA; Sampson HA J Allergy Clin Immunol; 2022 Apr; 149(4):1373-1382.e12. PubMed ID: 34653515 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. Bird JA; Spergel JM; Jones SM; Rachid R; Assa'ad AH; Wang J; Leonard SA; Laubach SS; Kim EH; Vickery BP; Davis BP; Heimall J; Cianferoni A; MacGinnitie AJ; Crestani E; Burks AW; J Allergy Clin Immunol Pract; 2018; 6(2):476-485.e3. PubMed ID: 29092786 [TBL] [Abstract][Full Text] [Related]
10. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. Greenhawt M; Sindher SB; Wang J; O'Sullivan M; du Toit G; Kim EH; Albright D; Anvari S; Arends N; Arkwright PD; Bégin P; Blumchen K; Bourrier T; Brown-Whitehorn T; Cassell H; Chan ES; Ciaccio CE; Deschildre A; Divaret-Chauveau A; Dorris SL; Dorsey MJ; Eiwegger T; Erlewyn-Lajeunesse M; Fleischer DM; Ford LS; Garcia-Lloret M; Giovannini-Chami L; Hourihane JO; Jay N; Jones SM; Kerns LA; Kloepfer KM; Leonard S; Lezmi G; Lieberman JA; Lomas J; Makhija M; Parrish C; Peake J; Perrett KP; Petroni D; Pfützner W; Pongracic JA; Quinn P; Robison RG; Sanders G; Schneider L; Sharma HP; Trujillo J; Turner PJ; Tuttle K; Upton JE; Varshney P; Vickery BP; Vogelberg C; Wainstein B; Wood RA; Bee KJ; Campbell DE; Green TD; Rouissi R; Peillon A; Bahnson HT; Bois T; Sampson HA; Burks AW N Engl J Med; 2023 May; 388(19):1755-1766. PubMed ID: 37163622 [TBL] [Abstract][Full Text] [Related]
11. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials. Ciaccio C; Goldsobel AB; Anagnostou A; Beyer K; Casale TB; Deschildre A; Fernández-Rivas M; Hourihane JO; Krawiec M; Lieberman J; Scurlock AM; Vickery BP; Smith A; Tilles SA; Adelman DC; Brown KR; Ann Allergy Asthma Immunol; 2022 Dec; 129(6):758-768.e4. PubMed ID: 35973655 [TBL] [Abstract][Full Text] [Related]
12. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849 [TBL] [Abstract][Full Text] [Related]
13. Peanut gastrointestinal delivery oral immunotherapy in adolescents: Results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study). Fauquert JL; Michaud E; Pereira B; Bernard L; Gourdon-Dubois N; Rouzaire PO; Rochette E; Merlin E; Evrard B; Clin Exp Allergy; 2018 Jul; 48(7):862-874. PubMed ID: 29665158 [TBL] [Abstract][Full Text] [Related]
15. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness. Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313 [TBL] [Abstract][Full Text] [Related]
16. Oral immunotherapy using boiled peanuts for treating peanut allergy: An open-label, single-arm trial. Grzeskowiak LE; Tao B; Aliakbari K; Chegeni N; Morris S; Chataway T Clin Exp Allergy; 2023 Mar; 53(3):327-336. PubMed ID: 36628520 [TBL] [Abstract][Full Text] [Related]
17. Safety of peanut (Arachis hypogaea) allergen powder-dnfp in children and teenagers with peanut allergy: Pooled summary of phase 3 and extension trials. Brown KR; Baker J; Vereda A; Beyer K; Burks AW; du Toit G; O'B Hourihane J; Jones SM; Norval D; Dana A; Shreffler W; Vickery BP; Casale T; Skeel B; Adelman D J Allergy Clin Immunol; 2022 Jun; 149(6):2043-2052.e9. PubMed ID: 34971646 [TBL] [Abstract][Full Text] [Related]
18. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK; Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664 [TBL] [Abstract][Full Text] [Related]
19. Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial. Michaud E; Evrard B; Pereira B; Rochette E; Bernard L; Rouzaire PO; Gourdon-Dubois N; Merlin E; Fauquert JL Trials; 2015 Apr; 16():197. PubMed ID: 25925398 [TBL] [Abstract][Full Text] [Related]
20. The 2S albumin allergens of Arachis hypogaea, Ara h 2 and Ara h 6, are the major elicitors of anaphylaxis and can effectively desensitize peanut-allergic mice. Kulis M; Chen X; Lew J; Wang Q; Patel OP; Zhuang Y; Murray KS; Duncan MW; Porterfield HS; W Burks A; Dreskin SC Clin Exp Allergy; 2012 Feb; 42(2):326-36. PubMed ID: 22288514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]